Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
source: pixabay.com

Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

According to a story from BioSpace, the biopharmaceutical company Zogenix, Inc., has recently announced the release of results from a phase 3 clinical trial testing the company's drug fenfluramine (marketed…

Continue Reading Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

New 5-Year Survival Data Available on Maralixibat for PFIC2

This year, the Digital International Liver Congress took place online from August 27-29, thanks to COVID-19. During the conference, biopharmaceutical company Mirum Pharmaceuticals announced data from its Phase 2 INDIGO…

Continue Reading New 5-Year Survival Data Available on Maralixibat for PFIC2
September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness

According to a story from Newswise, September is recognized as Pulmonary Fibrosis Awareness Month. This includes idiopathic pulmonary fibrosis (IPF), or disease without an identifiable cause. In the midst of…

Continue Reading September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
New Findings to be Presented on Recently Approved Neuromyelitis Optica Drug
source: pixabay.com

New Findings to be Presented on Recently Approved Neuromyelitis Optica Drug

According to a story from BioSpace, Genentech (of the Roche Group) has announced its plans to present new data related to its drug satralizumab-mwge (marketed as Enspryng™) at the upcoming…

Continue Reading New Findings to be Presented on Recently Approved Neuromyelitis Optica Drug